$Ginkgo Bioworks (DNA.US)$
There's no choice but to ride this big wave.

$Ginkgo Bioworks (DNA.US)$
The research collaboration announcement between Ginkgo Bioworks and Universal Cells may accelerate the development of next-generation cell therapy for cancer.
The US December employment statistics announced on January 5 showed a significant increase of 0.256 million in the number of non-agricultural sector employees, exceeding market Financial Estimates, and the unemployment rate also dropped to 4.1%.
This strong employment statistic widened the view that the pace of the FRB rate cuts would slow down, putting downward pressure on the entire stock market.
I think it is highly likely that the stock price of Ginkgo Bioworks has also been influenced by this market trend and may have declined.
The drop in Ginkgo Bioworks' stock price is believed to be mainly due to the overall market decline trend driven by strong employment statistics, as well as changes in the company's specific financial situation and market valuation.
It is unlikely that the announcement of a research collaboration itself is a direct cause of the stock price drop, rather, it is thought to have a high potential to strengthen the company's technological capabilities and market position in the long term.

$Ginkgo Bioworks (DNA.US)$
The stock price of Gingko Bioworks Holdings (DNA) is soaring.
Announced a 5-year partnership with Google Cloud, working on developing large-scale language models on Google Cloud's AI platform, which is being recognized and has led to increased investor expectations, resulting in a rise in stock price.

$Ginkgo Bioworks (DNA.US)$
Entered Hello holders, I look forward to your support and plan to take a long-term view.
With a small amount of capital, I added it to the portfolio with expectations ┏○ﾍﾟｺｯ

$Ginkgo Bioworks (DNA.US)$
I believed

$Ginkgo Bioworks (DNA.US)$
I will summarize since a lot of information has been given at once.
1. Announcement by Ginkgo Automation: Jason Kelly announced Ginkgo Bioworks' new product line, 'Ginkgo Automation'. This enables research support using robotics.
2. Prohibition measures from Russia: Ginkgo Bioworks CEO Jason Kelly is included in the prohibition list from Russia.
3. Evaluation from Morgan Stanley: Morgan Stanley has set a target price of $40 for Ginkgo Bioworks. (Considering Tejas Savant's low success rate and negative average return performance, his rating is not suitable as an investment decision criterion...)
4. Mark from Ginkgo will provide information for investors at the conference organized by Morgan Stanley on September 6th.
5. Contract with CDC: Ginkgo Bioworks...

$Ginkgo Bioworks (DNA.US)$
Until it reaches the point of being delisted, or around $500, we will thoroughly adhere to the Buy & Hold strategy. (Considering the relationships with the government, Palantir, Google, Cathie Wood, and Bill Gates, once it has reached this point, the possibility of delisting is almost nonexistent...)
It is often a concern that it will end up like Amyris, which filed for bankruptcy last year, but since the failure was due to a consumer brand, I don't think it will follow the same path. With remaining cash of $0.9 billion, I believe there will be no issues for at least about 2 years. In fact, such low-level discussions are no longer relevant.
Although the performance is still lacking, it is evolving rapidly.
The utilization of AI through the partnership with Google (considering that Google developed AlphaFold) is surprising. What's remarkable is that Shyam Sankar, who became the chairman of Ginkgo Bioworks in August last year, has held various positions at Palantir and is widely knowledgeable in AI, becoming the chairman. (He is currently also the Chief Technology Officer at Palantir).

$Tesla (TSLA.US)$ The US President has strengthened emissions regulations to accelerate EV sales! The images published in EconomicTimes are translated clippings. Does this... support Tesla with national policy?
Joe Biden set to crack down on auto emissions to accelerate EV sales - The Economic Times